On Monday, Needham analysts increased their price target for iRhythm Technologies (NASDAQ:IRTC) shares to $112 from the previous $96, while reaffirming a Buy rating on the stock. The medical device company, currently valued at $2.82 billion, has shown strong momentum with a 5.85% gain in the past week.
According to InvestingPro analysis, the stock is trading slightly above its Fair Value, with 8 key insights available to subscribers. The adjustment comes after iRhythm Technologies provided revenue guidance for 2024 that exceeded its earlier projections, suggesting that fourth-quarter revenue for 2024 would surpass $160 million, which is higher than the $157 million consensus estimate.
The company's robust performance is attributed to a record number of new account openings for its Zio monitor and Zio AT products. With an impressive revenue growth of 18.45% and a healthy gross margin of 67.83%, iRhythm demonstrates strong operational efficiency. Additionally, iRhythm's integration with Epic Aura has begun to gain traction, potentially becoming a key growth catalyst in 2025. The firm has also issued revenue guidance for 2025 in the range of $675-685 million, topping the consensus estimate of $680 million.
Despite facing regulatory and legal expenses that affected its 2024 adjusted EBITDA, analysts believe that the market's expectation of an 8% adjusted EBITDA margin for 2025, which implies an improvement of approximately 1,000 basis points year over year, might be somewhat optimistic.
While InvestingPro data shows the company isn't currently profitable, its strong liquidity position with a current ratio of 6.27 provides financial flexibility. Get the complete financial picture with InvestingPro's comprehensive research report, part of our coverage of 1,400+ US stocks.
In support of their positive outlook, Needham analysts have reiterated their Buy rating for iRhythm Technologies. They have raised their price target to $112, adjusting their valuation metric to reflect 2026 sales projections. This revised target reflects the analysts' confidence in iRhythm's growth trajectory and the potential for increased profitability in the coming years.
In other recent news, iRhythm Technologies has seen a considerable revenue increase of 18.4% year-over-year, reaching $147.5 million in its third-quarter financial results. Oppenheimer has reiterated its Outperform rating on iRhythm, raising the price target to $120 from the previous $105, indicating confidence in the company's long-term prospects. The firm's analysts have highlighted the strategic complementarity of iRhythm's asset to larger companies in the healthcare sector.
iRhythm has also reported significant changes to its corporate governance structure, amending its 2016 Equity Incentive Plan and updating its Code of Conduct. The company has entered into a technology licensing agreement with BioIntelliSense to enhance its cardiac monitoring solutions, further contributing to its growth.
Despite facing regulatory challenges, iRhythm has registered over 1 million patients and expanded internationally. The company anticipates a commercial launch of the Zio monitor in Japan in the first half of 2025. Lastly, iRhythm's 2024 revenue outlook is projected to be between $582.5 million and $587.5 million, signifying promising future developments for the company.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.